Rocket Pharma

$16.91 0.00% ($0.00)
  • 1D
  • 1W
  • 1M
  • 1Y
  • 5Y
  • YTD

Get ready to invest

Subscribe

About Rocket Pharma

Rocket Pharmaceuticals, Inc. is a clinical-stage biotechnology company. The Company is focused on developing gene therapy treatment options for rare, devastating diseases. The Company’s multi-platform development approach applies the well-established lentiviral vector (LVV) and adeno-associated viral vector (AAV) gene therapy platforms. The Company’s lead clinical program is a LVV-based gene therapy for the treatment of Fanconi Anemia (FA), a genetic disease that leads to bone marrow failure and potentially cancer. Its additional pipeline programs for bone marrow-derived disorders are for Pyruvate Kinase Deficiency (PKD), Leukocyte Adhesion Deficiency-I (LAD-I) and Infantile Malignant Osteopetrosis (IMO). The Company is also developing an AAV-based gene therapy program for pediatric heart failure indication, Danon disease.

Stock Analysis

last close $16.23
1-mo return -2.6%
3-mo return 96.5%
avg daily vol. 731.23T
52-week high 37.44
52-week low 7.57
market cap. $1.0B
forward pe -
annual div. -
roe -38.3%
ltg forecast -
dividend yield -
annual rev. $--
inst own. -
baraka

Subscribe now for daily local and international financial news

Subscribe